Thank you for Subscribing to Healthcare Business Review Weekly Brief
Regenerative medicine holds immense potential for transforming organ transplantation. While significant challenges remain, ongoing research and technological advancements are paving the way for a future where cell-based therapies can revolutionize the field and improve the lives of countless patients.
FREMONT, CA: Organ transplantation serves as a critical life-saving procedure for individuals with end-stage organ failure. Despite its significance, the persistent shortage of donor organs and the associated risk of rejection pose substantial challenges. Regenerative medicine presents a promising alternative by leveraging the body's natural capacity for repair and regeneration.
Advancements in Cellular Therapies for Organ Transplantation
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Cellular therapies, which leverage the transplantation of cells or tissues, hold transformative potential for organ transplantation by enhancing organ preservation, improving graft function, and addressing rejection.
Cellular therapies can play a crucial role in protecting donor organs in the realm of organ preservation. Mesenchymal stem cells (MSCs), for instance, have demonstrated the ability to mitigate ischemia-reperfusion injury—an often severe complication arising when blood flow returns to an organ after ischemia (restricted blood supply). This protective effect safeguards organ integrity and extends the duration for which organs can be preserved, thereby increasing the available donor pool.
Cellular therapies further enhance graft function by promoting tissue regeneration and modulating immune responses. Stem cells can aid in regenerating damaged tissues within transplanted organs, improving overall function and reducing the likelihood of rejection. Additionally, regulatory T cells have immunomodulatory properties that can suppress immune responses, minimizing the need for extensive immunosuppressive therapies.To address organ rejection, novel approaches like chimeric antigen receptor (CAR) T-cell therapy are being explored.
More in News